FDA 2026 Draft Guidance: What Pharmaceutical Manufacturers Need to Know About CCIT

FDA’s 2026 Draft Guidance on Container Closure Systems for Human Drugs and Biological Products introduces updated recommendations for container closure integrity testing (CCIT), with particular emphasis on sterile products, method validation, worst-case conditions, stability studies, transportation and storage, and advanced deterministic integrity testing technologies.

 

In August 2026, the U.S. Food and Drug Administration (FDA) issued the draft guidance Container Closure Systems for Human Drugs and Biological Products. The draft guidance provides FDA’s current thinking on the risk-based evaluation and control of container closure systems (CCSs) used for human drugs and biological products. If finalized, it will supersede the 1999 guidance and the 2002 Questions and Answers on container closure systems.

For pharmaceutical manufacturers developing sterile products, the new FDA draft guidance places particular emphasis on container closure integrity testing (CCIT) as an important component of CCS protection and lifecycle quality assessment.

Important: The FDA document is a draft guidance and contains nonbinding recommendations. It is marked “Draft — Not for Implementation.”

 

1. What Is CCIT and Why Is It Important for Sterile Products?

Container Closure Integrity Testing (CCIT) is used to evaluate the integrity of a Container Closure System (CCS) and ensure that the product is protected from the ingress of environmental factors.

According to the FDA draft guidance, CCIT has three key applications for sterile products:

Demonstrating sterile barrier suitability: CCIT can demonstrate that the selected CCS is suitable to provide an adequate sterile barrier.

Validating manufacturing parameters: CCIT can be used to validate relevant manufacturing parameters, such as capping parameters, and as an in-process test for appropriate CCS closure.

Demonstrating integrity throughout shelf life: CCIT can demonstrate that the CCS maintains its integrity under labeled storage conditions through expiry, helping protect product quality and sterility, where applicable.

The FDA therefore positions CCIT as an important element of the overall protection function of a CCS rather than simply as a leak detection test.

 

2. FDA Requirements for CCIT Method Selection and Method Validation

The FDA draft guidance recommends that the selected CCIT method be appropriately validated for the specific CCS.

The CCIT method should include:

• Method validation for the specific CCS;
• Test sensitivity information;
• Negative controls; 
• Positive controls.

When selecting an appropriate CCIT method, manufacturers should consider:

1. The type of CCS;
2. The intended use of the CCS;
3. The sensitivity of the test method; 
4. The storage conditions of the drug product.

Importantly, worst-case conditions should be considered and represented when selecting a CCIT method.

This means that CCIT method selection should not be based solely on routine laboratory conditions. The test strategy should reflect the actual risks that the container closure system may experience throughout manufacturing, transportation, storage, and the product lifecycle.

 

CCIT Testing Under Extreme Temperature Conditions

One of the notable points in the FDA 2026 draft guidance is its discussion of transient loss of container closure integrity under extreme storage or shipping conditions.

For example, rubber stoppers may temporarily lose their elastic properties at extremely low temperatures. During this period, the container closure may temporarily lose integrity, allowing gas to enter the container. After the container is removed from the extreme temperature, the elastomer may reseal and trap the ingressed gas.

If CCIT is performed only after the container has returned to normal temperature, this transient loss of integrity may not be detected.

Therefore, the FDA recommends that manufacturers consider CCIT methods that can be performed under extreme temperature conditions, such as freezing conditions.

This recommendation is particularly relevant to pharmaceutical products that require cold-chain storage, frozen storage, freeze-thaw studies, or temperature-controlled transportation.

 

3. Deterministic vs. Probabilistic CCIT Methods

The FDA draft guidance specifically encourages the use of innovative, advanced, and deterministic integrity testing technologies.

Probabilistic integrity testing methods may also be acceptable; however, FDA notes that such methods can present challenges in their design, development, validation, and implementation.

The FDA also emphasizes that each CCIT method has its own advantages and disadvantages, which should be considered before selecting a test method.

For method selection and evaluation, FDA refers manufacturers to USP General Chapter <1207>, Package Integrity Evaluation — Sterile Products, and its associated subchapters.

 

What Is a Deterministic CCIT Method?

Deterministic integrity testing methods generally generate objective, instrument-based measurements and are designed to provide reproducible results with defined test parameters.

Examples of commonly used deterministic or quantitative leak detection technologies include:

• Helium leak testing;
• Pressure decay testing;
• Vacuum decay testing; and
• High-voltage leak detection (HVLD).

The appropriate technology should always be selected according to the specific CCS, product characteristics, intended use, required sensitivity, and test conditions.

 

4. Examples of CCIT Methods for Different Container Closure Systems

Container Closure System	Material of Construction (MOC)	Examples of CCIT Methods
Vials or bottles with closures	Glass or plastic	Helium leak testing; pressure and/or vacuum decay; dye ingress; mass extraction testing
Ampoules	Glass	Helium leak testing; pressure and/or vacuum decay; dye ingress; high-voltage leak detection (HVLD)
Blow-Fill-Seal (BFS) containers	Plastic	Helium leak testing; pressure and/or vacuum decay; dye ingress; high-voltage leak detection (HVLD)
Prefilled syringes / cartridges	Glass or plastic	Helium leak testing; pressure and/or vacuum decay; dye ingress; mass extraction testing
Tubes	Plastic / aluminum	Dye ingress
Flexible bags	Plastic	Helium leak testing; pressure and/or vacuum decay; dye ingress; mass extraction testing; internal pressurization (bubble emission testing)
Blister packaging	Plastic / aluminum foil	Helium leak testing; dye ingress; seal integrity testing; burst/creep testing
Sachets / pouches	Foil/paper; plastic	Pressure and/or vacuum decay; dye ingress

The FDA draft guidance provides examples of commonly used CCIT methods for different types of CCSs. FDA notes that the table is not intended to represent the only testing methods that may be used to demonstrate container integrity.

 

Special Considerations for Blow-Fill-Seal (BFS) Packaging

The FDA draft guidance highlights that container closure defects can be a major concern for Blow-Fill-Seal (BFS) operations.

For BFS packaging, FDA recommends using a reliable and sensitive leak detection method to inspect each unit of each batch. The guidance also notes that certain leak detection technologies, including high-voltage leak detection and vacuum leak detection, can be adapted for in-line inspection to ensure container integrity.

This makes 100% in-line CCIT inspection particularly relevant to high-throughput BFS manufacturing and automated packaging inspection.

 

5. CCIT Requirements for Stability Studies

The FDA draft guidance states that all sterile products should be tested to verify maintenance of sterility over the drug product’s shelf life.

Because of the inherent limitations of sterility testing, FDA encourages manufacturers to perform CCIT in lieu of sterility testing as a component of a stability program to demonstrate that containers can maintain sterility throughout the product’s shelf life.

For stability studies, manufacturers should consider:

• Testing the drug product in its final commercial CCS;
• Including CCS evaluation in the stability protocol, as appropriate;
• Performing CCIT as part of the stability program for sterile products; 
• Evaluating the impact of postapproval CCS changes on stability.

The FDA draft guidance also states that if abnormalities are observed in the CCS during stability studies, the manufacturer should investigate the issue.

 

This reinforces an important principle:

CCIT should be considered a lifecycle quality assessment rather than a one-time packaging qualification activity.

 

6. Additional CCIT Considerations for Shipping, Handling, and Storage

The integrity of a CCS may be affected by transportation, handling, temperature fluctuations, and other environmental stresses.

For sterile products, manufacturers should consider evaluating CCS integrity following shipping validation.

For products exposed to freeze-thaw cycles or thermal cycling, FDA recommends evaluating CCS integrity and functionality after the relevant studies. The assessment may include:

• CCIT using appropriate methods listed in Table 3 of the guidance;
• Visual inspection for cracks;
• Visual inspection for breakage; 
• Inspection for particulate defects.

For cold-chain products, this consideration is particularly important because the CCS may experience temperature conditions that differ significantly from routine laboratory testing conditions.

 

7. CCIT Data in FDA Regulatory Submissions

The FDA draft guidance also provides recommendations concerning CCS information submitted in regulatory applications.

Marketing Applications: NDA, ANDA, and BLA

For drug substances, the CCS information may be included in eCTD Module 3.2.S.6. For sterile drug substances, FDA recommends providing container closure integrity information.

For drug products, eCTD Module 3.2.P.2.5 should demonstrate container closure integrity for sterile products, while Module 3.2.P.3.5 addresses process validation and/or evaluation for the primary container closure.

Investigational Applications: IND and IDE

For investigational applications, FDA may request additional CCS quality information when specific safety concerns exist, including proposals involving new or novel packaging materials or atypical delivery systems.

 

Drug Master Files (DMFs)

The FDA draft guidance indicates that Type II DMFs may be used to provide container closure information for drug substances and, where applicable, CCIT information for sterile drug substances.

Type III DMFs may contain information regarding packaging materials and components, including suitability evaluation data supporting the acceptability of packaging materials or components for their intended use.

 

8. Postapproval Changes to Container Closure Systems

Changes to a CCS can potentially affect the identity, strength, quality, purity, or potency of a drug product.

The FDA draft guidance states that changes to a CCS should be based on a risk assessment evaluating potential effects on product quality, safety, and effectiveness.

Relevant changes may include:

• Changes to CCS components;
• Changes to materials of construction (MOC);
• Changes to suppliers;
• Changes to manufacturing processes;
• Changes to capping processes; 
• Changes to device constituent parts of combination products.

Depending on the nature and risk of the change, additional CCIT data and stability data may be needed to support the regulatory assessment.

 

CCIT for Combination Products

When a CCS is also a device constituent part of a combination product, container closure integrity is not the only consideration.

In addition to assessing the container closure function, manufacturers should evaluate the device constituent part’s function and drug delivery performance, including performance after shipping, during storage, and during use.

 

9. CCIT for Bulk Containers Used for Drug Substances

The FDA draft guidance also addresses bulk containers used to store or transport drug substances and bulk drug products.

A bulk container should provide adequate protection against deterioration or contamination during the specified storage and transportation conditions.

For sterile drug substances, the protection provided by the bulk container should be appropriately evaluated, including container closure integrity where applicable.

This expands the practical scope of CCIT beyond conventional finished-product packaging to include bulk pharmaceutical packaging and drug substance storage and transportation systems.

 

10. CCIT Does Not Mean Sterility

An important distinction should be made between container closure integrity and product sterility.

CCIT evaluates the physical integrity and protective capability of the container closure system. It demonstrates whether the packaging system can maintain an effective barrier against environmental ingress and leakage.

Sterility, on the other hand, describes the microbiological state of the product at a specific sampling or testing point.

Therefore:

CCIT demonstrates the integrity of the physical barrier; it does not, by itself, establish that a product is sterile.

The role of CCIT is to demonstrate that the CCS can maintain the protective barrier required to help preserve product quality and sterility throughout storage, transportation, and the product lifecycle.

 

11. Secondary Packaging and Container Closure Integrity

The FDA draft guidance recognizes that secondary packaging components may provide additional protection to the primary CCS.

For example, secondary packaging may provide additional protection against:

• Moisture;
• Light;
• Microbial contamination;
• Mechanical stress; 
• Rough handling.

When secondary packaging provides an additional protective function, appropriate assessments may be required, including seal integrity testing and stability studies, depending on its intended function.

However, the integrity evaluation of secondary packaging should not be automatically treated as equivalent to CCIT of the primary container closure system.

 

12. What the FDA 2026 Draft Guidance Means for Pharmaceutical CCIT

The FDA 2026 draft guidance reflects a broader lifecycle and risk-based approach to container closure integrity.

For pharmaceutical manufacturers, several trends are particularly important:

1. CCIT is becoming increasingly integrated into CCS lifecycle management

CCIT should be considered across development, manufacturing, stability, transportation, storage, and postapproval changes rather than as an isolated laboratory test.

 

2. Worst-case conditions are increasingly important

CCIT method selection should represent relevant worst-case conditions, including extreme temperature and transportation scenarios.

 

3. In-situ testing under extreme conditions deserves greater attention

For products exposed to freezing or other extreme temperatures, performing CCIT only after returning samples to room temperature may fail to identify transient integrity failures.

 

4. Deterministic technologies are gaining regulatory relevance

FDA explicitly encourages innovative, advanced, and deterministic integrity testing technologies, creating opportunities for more quantitative, sensitive, and reproducible CCIT approaches.

 

5. Automated and 100% in-line inspection can play an important role

For high-risk packaging processes such as BFS, reliable and sensitive in-line leak detection can be used to inspect each unit of each batch.

 

6. CCIT is increasingly connected with global pharmaceutical development

For pharmaceutical companies developing products for global markets, CCIT strategies should consider international regulatory expectations, packaging configurations, transportation conditions, stability requirements, and lifecycle changes.

 

Zholion CCIT Research and Technical Capabilities

As a CCIT one-stop technical service provider, Zholion provides comprehensive container closure integrity testing services covering both deterministic and probabilistic integrity testing technologies.

Zholion’s CCIT research capabilities support pharmaceutical packaging studies throughout the product lifecycle, including:

• IND development;
• NDA/BLA development;
• CCIT method development and validation;
• Stability studies;
• Shipping and transportation studies;
• Storage studies;
• Postapproval CCS changes;
• Flexible packaging;
• Rigid packaging;
• Bulk API containers;
• Stainless steel (SUS) packaging systems; 
• Secondary packaging systems.

 

Advanced Helium Leak Testing for CCIT

Zholion has established technical platforms for both room-temperature helium leak testing and low-temperature helium leak testing, supporting CCIT studies and Maximum Allowable Leakage Limit (MALL) value research throughout the lifecycle of pharmaceutical packaging systems.

In response to the FDA draft guidance’s recommendation to consider CCIT methods that can be performed under extreme temperature conditions, Zholion has developed advanced in-situ ultra-low-temperature CCIT technologies, including:

In-situ helium leak testing under ultra-low-temperature conditions; and

In-situ laser-based CCIT under ultra-low-temperature conditions.

These technologies enable CCIT evaluation under conditions where conventional post-conditioning testing may not adequately capture transient loss of container closure integrity.

Zholion has delivered ultra-low-temperature CCIT research projects for pharmaceutical companies and packaging manufacturers, helping customers evaluate container closure integrity under challenging temperature conditions and supporting pharmaceutical products intended for global markets.

 

Supporting Pharmaceutical Packaging Compliance and Global Market Access

Zholion has participated in the development and application of seven test method standards associated with China’s pharmacopoeial guidance on container closure integrity.

With extensive practical experience in CCIT research and testing, Zholion supports pharmaceutical manufacturers in addressing container closure integrity challenges for products intended for markets in the United States, Europe, and other international markets.

From CCIT method development and validation to stability, transportation, extreme-temperature, and postapproval studies, Zholion provides lifecycle-oriented CCIT solutions designed to help pharmaceutical companies manage packaging integrity risks and strengthen their global regulatory readiness.